View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 4, 2011

FDA approves Abbott’s Xience Prime drug-eluting stent

The US Food and Drug Administration (FDA) has approved Abbott's next-generation Xience Prime everolimus-eluting coronary stent system, used to treat coronary artery disease.

The US Food and Drug Administration (FDA) has approved Abbott’s next-generation Xience Prime everolimus-eluting coronary stent system, used to treat coronary artery disease.

The Xience Prime uses cobalt chromium technology and features a ‘peak-to-valley’ design that gives the stent longitudinal strength and stability.

The stent uses a drug and biocompatible polymer similar to that of the Xience V everolimus-eluting coronary stent system.

The approval is backed by results from a prospective, open-label Spirit Prime clinical trial, which reported the Xience Prime met its primary endpoint, with low rates of target lesion failure after one year.

Xience Prime is available in the US, Europe, the Middle East and most of Asia.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Hospital Management